title: [Reocclusion following thrombolytic treatment in acute myocardial infarct].
abstract: Currently there are five thrombolytic substances undergoing evaluation: streptokinase, tissue plasminogen activator, acylated plasminogen streptokinase activator complex, urokinase and single chain urokinase plasminogen activator. Equal results for mortality reduction (25 per cent) and reocclusion (6-24 per cent) has been reported in the literature for the five substances. Reocclusion can be divided into an early (greater than 24 hours) and a late phase. The early phase is most likely due to an imbalance between thrombolysis and the formation of a thrombus. During late reocclusion there is formation of a thrombus on the underlying coronary plaque or residual thrombotic mass, following thrombolytic therapy. The residual stenosis following thrombolysis seems to be the most important prognostic factor for reocclusion. A residual stenosis of over 75 per cent is unfavourable. Early reocclusion is prevented through simultaneous antithrombotic and thrombolytic therapy. Patients with a residual stenosis of over 75 per cent should be considered for some sort of active intervention to prevent late reocclusion.
authors.affiliation: Medicinska kliniken, Danderyds sjukhus, Karolinska Institutet, Danderyd.
authors.forename: G
authors.initials: G
authors.lastname: Modin
authors.forename: E
authors.initials: E
authors.lastname: Näslund
authors.forename: N
authors.initials: N
authors.lastname: Rehnquist
authors.forename: L E
authors.initials: LE
authors.lastname: Strandberg
mesh_terms: D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D001777:Blood Coagulation; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D012008:Recurrence; D015912:Thrombolytic Therapy
chemical_list: D000925:Anticoagulants